Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

References

• Svenska Lymfomregistret Rapport för år 2000-2005 (the Swedish lymphoma registry report 2000-2005), Svenska Lymfomgruppen, Sveriges Onkologiska Centra [Online]. Available from: http://www.ocsyd.lu.se/VP-verksamhet/Kvalitetsreg/RapportLymfom2000-2005.pdf.
   Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–91
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–7
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 1306–14
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–301
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–32
   PubMed Web of Science ®Google Scholar
• Fisher RI. Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Clin Adv Hematol Oncol 2005; 3: 544–6
   Google Scholar
• Committee for medicinal products for human use post-authorisation summary of positive opinion for Mabthera [Online]. [cited 2007 April]; Available from: www.emea.europa.eu/pdfs/human/opinion/20477106en.pdf.
   Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–8
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416–23
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–95
   PubMed Web of Science ®Google Scholar
• EORTC20981: Clinical Study Report – EORTC20981 (M39022) – Chimeric anti-CD20 monoclonal antibody (MabThera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: A phase III randomized clinical trial – Intergroup Collaborative Study. Research report 1016350 – December, 2005.
   Google Scholar
• Berto P, Lopatriello S, Arcaini L, Del Poeta G, Martellin M, Gargantini L, et al. Costo-efficacia di rituximab nella terapia di mantenimento in soggetti affetti da linfoma non-Hodgkin follicolare refrattario o recidivante. PharmacoEconomics-Italian Research Articles 2007; 9: 9–19
   Google Scholar
• General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) [Online]. [cited 2007 April]; Available from: http://www.lfn.se/upload/Foretag/ENG_lfnar2003-eng.pdf.
   Google Scholar
• Läkemedelsportalen (Swedish national pharmaceuticals price list) [Online]. [cited 2007 April]; Available from: www.fass.se.
   Google Scholar
• Prislista Akademiska sjukhuset i Uppsala (Uppsala University Hospital price list) [Online]. [cited 2007 April]; Available from: www.externt9.lul.se/svn/uppsala07.xls.
   Google Scholar
• Prislista Universitetsjukhuset MAS-Malmö (Malmö University Hospital price list) [Online]. [cited 2007 April]; Available from: www.srvn.org/prislista.htm.
   Google Scholar
• KPP-databasen (the national inpatient case-costing database), The Swedish Association of Local Authorities and Regions [Online]. [cited 2007 April]; Available from: stat.skl.se/kppprod/index.htm.
   Google Scholar
• Martin Erlanson, Norrlands University Hospital, Umeå; Hans Hagberg, Uppsala University Hospital; Uppsala; Eva Kimby, Karolinska University Hospital, Huddinge; Thomas Relander, Lund University Hospital, Lund; [personal communication, April 2007].
   Google Scholar
• Utility values in Follicular Lymphoma. Oxford Outcomes Ltd 2005.
   Google Scholar
• U Persson, J. Hjelmgren [Health services need knowledge of how the public values health]. Lakartidningen 2003;100:3436–7.
   Google Scholar